首页> 外文期刊>Therapeutic Drug Monitoring >Effect of digoxin fab antibody on the measurement of total and free digitoxin by fluorescence polarization and a new chemiluminescent immunoassay.
【24h】

Effect of digoxin fab antibody on the measurement of total and free digitoxin by fluorescence polarization and a new chemiluminescent immunoassay.

机译:地高辛fab抗体对荧光偏振和新型化学发光免疫测定法测量总和游离洋地黄毒苷的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

Digoxin fab antibody (Digibind; Burroughs Wellcome, Research Triangle Park, NC, USA) is used in the treatment of digoxin overdose. The effect of digibind on the measurement of total and free digoxin has been extensively studied. However, the effect of digibind on digitoxin measurements has not been studied thoroughly. The authors studied the effect of digibind on the measurement of total and free digitoxin in vitro using the fluorescence polarization immunoassay and a new chemiluminescent immunoassay. We also studied the capability of digibind to bind digitoxigenin, the major aglycon metabolite of digitoxin. Digibind neutralized both digitoxin and digitoxigenin in vitro, as evidenced by significant reductions in free digitoxin and digitoxigenin (measured as digitoxin equivalent) concentrations. Digibind caused negative interference in the measurement of total digitoxin concentrations by both fluorescence polarization and chemiluminescent assays. However, the magnitude of negative interference was significantly higher with the chemiluminescent assay. For example, in a serum pool supplemented with 80 ng/mL of digitoxin, the concentrations of total and free digitoxin measured by the fluorescence polarization immunoassay were 82.1 ng/mL and 3.3 ng/mL respectively. In the presence of 5 microg/mL of Digibind, the corresponding total and free digitoxin concentrations were 73.9 ng/mL and none detected, respectively. In another serum pool supplemented with 70 ng/mL of digitoxin, the concentrations of total and free digitoxin as measured by the chemiluminescent assay were 69.1 ng/mL and 3.8 ng/mL, respectively. In the presence of 5 microg/mL of Digibind, the corresponding total and free digitoxin concentrations were 29.0 ng/mL and none detected, respectively. Because this effect may also occur in vivo, the progress of Digibind therapy in treating a patient with digitoxin overdose may be monitored by measuring the free digitoxin concentrations.
机译:地高辛Fab抗体(Digibind; Burroughs Wellcome,美国北卡罗来纳州研究三角公园)用于治疗地高辛过量。地高辛对总地高辛和游离地高辛的影响已被广泛研究。但是,尚未彻底研究地比拜因对洋地黄毒苷测定的影响。作者研究了使用荧光偏振免疫测定法和新的化学发光免疫测定法在体外测定总地平和总洋地黄毒苷的作用。我们还研究了digibind结合洋地黄毒苷(洋地黄毒苷的主要糖苷代谢产物)的能力。 Digibind在体外中和了洋地黄毒苷和洋地黄毒苷,这由游离洋地黄毒苷和洋地黄毒苷(以洋地黄毒当量计)的浓度显着降低所证明。 Digibind在荧光偏振和化学发光测定中对总洋地黄毒素浓度的测量造成负面干扰。然而,化学发光测定法产生的负面干扰幅度明显更高。例如,在补充了80 ng / mL洋地黄毒素的血清池中,通过荧光偏振免疫测定法测得的总洋地黄毒素和游离洋地黄毒素的浓度分别为82.1 ng / mL和3.3 ng / mL。在存在5 microg / mL Digibind的情况下,相应的总和自由洋地黄毒蛋白浓度为73.9 ng / mL,没有检测到。在另一个补充有70 ng / mL洋地黄毒素的血清库中,化学发光法测得的总和游离洋地黄毒素的浓度分别为69.1 ng / mL和3.8 ng / mL。在存在5 microg / mL的Digibind时,相应的总和游离洋地黄毒苷浓度分别为29.0 ng / mL,没有检测到。由于这种作用也可能在体内发生,因此可以通过测量游离的洋地黄毒素浓度来监测洋地黄毒素过量患者的Digibind治疗进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号